drugset / Trial / NCT01896284
Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor
Phase 4
Completed
46 enrolled
Barcelona Macula Foundation
Bayer · collabTFS Trial Form Support · collab
NaSingle-groupOpen-labelTreatment
Summary
Patients with neovascular age-related macular degeneration who do not respond to usual treatment with conventional medications may respond to a new drug of the same class which is designed to block a larger fraction of proangiogenic factors.
Timeline
- Start
- 2013-07
- Primary completion
- 2014-11
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 0.5 mg | Intravitreal |